178 related articles for article (PubMed ID: 10897004)
61. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
62. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
[TBL] [Abstract][Full Text] [Related]
63. Establishment and Verification of a Scoring Model for the Differential Diagnosis of Pancreatic Cancer and Chronic Pancreatitis.
Zhang H; Han W; Jin M; Lai Y; Wang X; Wang J; Yao Y; Wu D; Qian J; Yang H
Pancreas; 2018 Apr; 47(4):459-465. PubMed ID: 29517635
[TBL] [Abstract][Full Text] [Related]
64. [Advances regarding tumor markers in bladder cancer].
Moreno Sierra J; Chicharro Almarza GJ; Torronteras Santiago JM; Ortega Heredia MD; Maestro de las Casas ML; Silmi Moyano A; Resel Estévez L
Actas Urol Esp; 1997 Mar; 21(3):195-205. PubMed ID: 9324884
[TBL] [Abstract][Full Text] [Related]
65. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
66. Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gąsiorowska A; Olakowski M; Dranka-Bojarowska D; Lampe P; Śmigielski J; Kujawiak M; Grzegorczyk J; Małecka-Panas E
Adv Med Sci; 2014 Sep; 59(2):288-92. PubMed ID: 25194335
[TBL] [Abstract][Full Text] [Related]
67. CA 242 is a new tumor marker for pancreatic cancer.
Röthlin MA; Joller H; Largiadèr F
Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
[TBL] [Abstract][Full Text] [Related]
68. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.
Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V
Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666
[TBL] [Abstract][Full Text] [Related]
69. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
[TBL] [Abstract][Full Text] [Related]
70. Tumor markers in pleural effusions.
Topolcan O; Holubec L; Polivkova V; Svobodova S; Pesek M; Treska V; Safranek J; Hajek T; Bartunek L; Rousarova M; Finek J
Anticancer Res; 2007; 27(4A):1921-4. PubMed ID: 17649796
[TBL] [Abstract][Full Text] [Related]
71. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
Firpo MA; Gay DZ; Granger SR; Scaife CL; DiSario JA; Boucher KM; Mulvihill SJ
World J Surg; 2009 Apr; 33(4):716-22. PubMed ID: 19082654
[TBL] [Abstract][Full Text] [Related]
72. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
73. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
74. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma.
Sakahara H; Endo K; Nakajima K; Nakashima T; Koizumi M; Ohta H; Hidaka A; Kohno S; Nakano Y; Naito A
Cancer; 1986 Apr; 57(7):1324-6. PubMed ID: 3456252
[TBL] [Abstract][Full Text] [Related]
75. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
Heptner G; Domschke S; Schneider MU; Domschke W
Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
[TBL] [Abstract][Full Text] [Related]
76. Can IL-2R alpha be a valuable marker along with CA 19-9 in the diagnosis of chronic pancreatitis and pancreatic cancer?
Kayhan B; Kayhan B; Akdoğan M
Int J Biol Markers; 2004; 19(3):196-202. PubMed ID: 15503821
[TBL] [Abstract][Full Text] [Related]
77. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis].
Basso D; Fabris C; Del Favero G; Panucci A; Piccoli A; Plebani M; Pedrazzoli S; Baccaglini U; Lise M; Burlina A
Minerva Med; 1986 Apr; 77(16):613-6. PubMed ID: 3458035
[TBL] [Abstract][Full Text] [Related]
78. Androstanediol glucuronide in patients with pancreatic cancer and in those with chronic pancreatitis.
Jansa R; Prezelj J; Kocijancic A; Osredkar J; Ferlic F
Horm Metab Res; 1996 Aug; 28(8):381-3. PubMed ID: 8886824
[TBL] [Abstract][Full Text] [Related]
79. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R
Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228
[TBL] [Abstract][Full Text] [Related]
80. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
